• Markets
    • icon
  • Companies
PNV · ASX

Polynovo Limited (ASX:PNV)

AU$1.39

 0.015 (1.091%)
ASX:Live
01/12/2023 04:10:47 PM
Hammer Bearish HALO Small HALO Ords HALO Growth HALO Balance Sheet +6
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PNV Overview

PNV Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PNV

Website

Polynovo Limited

Telephone

61.3.8681.4050

Address

Unit 2 320 Lorimer Street Port Melbourne, Victoria (VIC) 3207

Description

Polynovo Ltd. engages in the provision biodegradable medical devices. It focuses on biodegradable temporizing matrix (BTM) product. It operates through the United States of America, and Australia and New Zealand geographical segment. The company was founded on August 12, 1998 and is headquartered in Port Melbourne, Australia.

PNV Price Chart

Key Stats

Market Cap

AU$955.97M

PE

EV/EBITDA

379.8

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.1 - 2.71

Trade Value (12mth)

AU$820,208.00

1 week

1.85%

1 month

14.58%

YTD

-32.6%

1 year

-32.27%

All time high

4.08

Key Fundamentals

EPS 3 yr Growth

14.300%

EBITDA Margin

-6.00%

Operating Cashflow

-$6m

Free Cash Flow Return

-11.10%

ROIC

-9.30%

Interest Coverage

-5.50

Quick Ratio

5.00

Other Data

Shares on Issue (Fully Dilluted)

690m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

5.12

PNV Announcements

Latest Announcements

Date Announcements

31 May 23

Notification regarding unquoted securities - PNV

×

Notification regarding unquoted securities - PNV

31 March 23

Application for quotation of securities - PNV

×

Application for quotation of securities - PNV

31 August 23

Webcast Recording - FY23 Results

×

Webcast Recording - FY23 Results

30 September 10

Annual Report and Full Year Financial Accounts (CZD-AU)

×

Annual Report and Full Year Financial Accounts (CZD-AU)

30 November 22

Share Purchase Plan (SPP) Offer

×

Share Purchase Plan (SPP) Offer

30 June 23

Appendix 3Y - Robyn Elliott

×

Appendix 3Y - Robyn Elliott

29 October 15

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 October 15

Annual Report to shareholders

×

Annual Report to shareholders

29 November 22

Cleansing Notice

×

Cleansing Notice

29 July 22

CEO Appointment - Swami Raote

×

CEO Appointment - Swami Raote

28 September 07

2007 Annual Report and Notice of AGM (MBP-AU)

×

2007 Annual Report and Notice of AGM (MBP-AU)

28 September 06

CEO presents at UBS Global Life Sciences Conference (NY)

×

CEO presents at UBS Global Life Sciences Conference (NY)

28 October 22

Chairman and CEO - AGM address to shareholders

×

Chairman and CEO - AGM address to shareholders

28 October 22

Results of 2022 Annual General Meeting

×

Results of 2022 Annual General Meeting

28 October 08

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

28 November 22

Application for quotation of securities - PNV

×

Application for quotation of securities - PNV

27 September 22

Notice of Annual General Meeting

×

Notice of Annual General Meeting

27 October 06

Metabolic Pharmaceuticals Limited - CEO presentation

×

Metabolic Pharmaceuticals Limited - CEO presentation

27 November 08

AGM Presentation

×

AGM Presentation

27 November 06

Corporate Presentation for Domestic Roadshow

×

Corporate Presentation for Domestic Roadshow

27 May 22

Director Share Purchase - David Williams

×

Director Share Purchase - David Williams

27 June 22

Ceasing to be a substantial holder from MUFG

×

Ceasing to be a substantial holder from MUFG

26 September 08

Annual Report to shareholders

×

Annual Report to shareholders

26 September 06

Annual Report/Notice of AGM

×

Annual Report/Notice of AGM

26 October 23

PolyNovo presents at Wilsons Drug and Device Conference

×

PolyNovo presents at Wilsons Drug and Device Conference

26 October 22

Hong Kong - Two cases, Two surgeons

×

Hong Kong - Two cases, Two surgeons

26 October 21

Results of 2021 Annual General Meeting

×

Results of 2021 Annual General Meeting

PNV Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.1 74.3 -300.0 Lock Lock Lock
     PE X Lock Lock Lock Lock 9,168.3 1,155.5 13,268.0 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 1,591.8 0.0 379.8 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 97.6 -6,182.7 56.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -0.2 -0.3 -0.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.03 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.02 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.6 -21.2 277.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 661 661 684 Lock Lock Lock
Basic m Lock Lock Lock Lock 661 661 684 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 29 41 65 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.6 42.1 57.4 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 16 26 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 8 16 19 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.3 107.4 19.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 26.8 39.2 29.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 73 61 70 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 2 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 38.5 175.9 -353.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -7.0 3.7 -6.0 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 0 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.0 91.8 -2,309.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -10.8 -0.6 -9.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -1 -5 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -1 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -9.8 74.1 -312.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -15.8 -2.9 -7.5 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 0 -2 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 4 0 2 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -4 6 -2 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 -5 48 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -3 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 58.8 33.2 -192.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.1 -0.1 -0.1 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 8 6 47 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 38 35 93 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 7 9 14 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 2 5 -31 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 16 17 27 Lock Lock Lock
Equity $m Lock Lock Lock Lock 22 18 65 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 29 27 80 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.5 -8.7 195.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.0 -3.4 -5.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -20.6 -6.7 -7.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -9.5 -0.8 -11.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -16.0 -4.2 -9.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -0.9 -7.3 -11.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -6.3 4.9 -5.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -1.1 3.1 7.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 10.1 27.3 -47.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.9 2.1 5.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.6 1.7 5.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 48.1 38.3 69.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -2.9 -26.5 -46.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 6.1 7.0 6.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 13.4 11.2 13.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 3.9 5.0 1.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 6.2 4.5 4.2 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.8 1.2 0.7 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.8 1.2 0.7 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -15.6 -2.8 -7.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -11.9 -3.3 -5.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.0 -3.4 -5.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.7 2.0 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -20.6 -6.7 -7.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -20.6 -6.7 -7.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 27.2 32.5 28.1 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 60.0 51.8 56.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 87.2 84.3 84.4 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 28.3 26.1 17.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 58.9 58.3 66.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

5.12%

Value ($M)

48

Prior Change

0.80%

7 Day Change

0.60%

1 Month Change

1.00%

3 Month Change

2.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PNV Shortsell

Frequently Asked Questions

The current share price of Polynovo Limited (PNV:ASX) is AU$1.39.
The 52-week high share price for Polynovo Limited (PNV:ASX) is AU$2.71.
The 52-week low share price for Polynovo Limited (PNV:ASX)? is AU$1.10.
The current TTM dividend payout for Polynovo Limited (PNV:ASX) is 0.00.
Polynovo Limited (PNV:ASX) does not pay a dividend.
Polynovo Limited (PNV:ASX) has a franking level of 0%.
Polynovo Limited (PNV:ASX) is classified in the Healthcare.
The current P/E ratio for Polynovo Limited (PNV:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.